Significance of AF4-MLL reciprocal fusion in t(4;11) leukemias?

Leukemia Research

Volumn 35, Issue 3, 2011, Pages 299-300

  Sanders, Daniel S ^a   Muntean, Andrew G ^a   Hess, Jay L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Leukemia; MLL AF4; Reciprocal translocations

Indexed keywords

AF4 MLL RECIPROCAL FUSION PROTEIN; HYBRID PROTEIN; UNCLASSIFIED DRUG;

ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 4; CHRONIC MYELOID LEUKEMIA; DISEASE MODEL; GENE MUTATION; HUMAN; LEUKEMIA CELL LINE; LEUKEMOGENESIS; MALIGNANT TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN METHYLATION;

EID: 79952105680     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.09.015     Document Type: Editorial

References (9)

1. Krivtsov A.V., Feng Z., Lemieux M.E., Faber J., Vempati S., Sinha A.U., et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 2008, 14:355-368.
2. Chen W., Li Q., Hudson W.A., Kumar A., Kirchhof N., Kersey J.H. A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy. Blood 2006, 108:669-677.
3. Metzler M., Forster A., Pannell R., Arends M.J., Daser A., Lobato M.N., et al. A conditional model of MLL-AF4 B-cell tumourigenesis using invertor technology. Oncogene 2006, 25:3093-3103.
4. Kumar A.R., Yao Q., Li Q., Sam T.A., Kersey J.H. t(4;11) leukemias display addiction to MLL-AF4 but not to AF4-MLL. Leuk Res 2011, 35:305-309.
5. Bursen A., Schwabe K., Ruster B., Henschler R., Ruthardt M., Dingermann T., et al. The AF4. MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4. Blood 2010, 115:3570-3579.
6. Rego E.M., Pandolfi P.P. Reciprocal products of chromosomal translocations in human cancer pathogenesis: key players or innocent bystanders?. Trends in Molecular Medicine 2002, 8:396-405.
7. Zheng X., Oancea C., Henschler R., Moore M.A., Ruthardt M. Reciprocal t(9;22) ABL/BCR fusion proteins: leukemogenic potential and effects on B cell commitment. PLoS One 2009, 4:e7661.
8. Armstrong S.A., Kung A.L., Mabon M.E., Silverman L.B., Stam R.W., Den Boer M.L., et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 2003, 3:173-183.
9. Mueller D., Bach C., Zeisig D., Garcia-Cuellar M.P., Monroe S., Sreekumar A., et al. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood 2007, 110:4445-4454.